Company comments AB InBev: Little to disappoint Adyen: 2H25 results – mixed results, soft guidance CVC Capital Partners: Executing well dsm-firmenich: Messy results Fagron: Beat on all lines, confident FY26 outlook to drive c.5% consensus EBITDA upgrade Flow Traders: EMEA saves the day KBC: Good results, opening up “jaws” further to 2028 Kinepolis: Canadian peer Cineplex 4Q25 results below consensus, January 2026 box office revenue up MICC: FX headwind leads to a 50bp margin miss in FY25 Montea:...
WDP's FY25 results were fully in line but the company surprised in already revealing its 2030 targets. We like such long-term visibility combined with very clear targets: €500m of yearly capex that can be auto-financed, delivering a +6% CAGR. WDP now has pan-European ambitions and aims to establish a presence in Italy and Spain. While the company has not delivered on its entrance into Germany, we think that opening itself to new countries is the right ambition to have at this stage. The plan loo...
Melexis: update on the share buy-back program Press release - Regulated Information Ieper, Belgium – 9 February 2026, 17.45 hrs CET Melexis reports the purchase of 10,000 Melexis shares on Euronext Brussels in the period from 2 February 2026 to 6 February 2026, related to the share buy-back program announced on 10 December 2025. Trade dateTotal shares purchasedAverage price (€)Min price (€)Max price (€)Buyback amount (€)2/2/2026-----2/2/2026-----2/2/2026-----2/2/20265,00053.8052.2056.55268,9952/2/20265,00053.1352.5053.45265,662TOTAL10,00053.4752.2056.55534,657 Under the current share bu...
Melexis: update over het aandeleninkoopprogramma Persbericht - Gereglementeerde informatie Ieper, België – 9 februari 2026, 17.45 uur CET Melexis meldt de aankoop van 10.000 Melexis-aandelen op Euronext Brussel in de periode van 2 februari 2026 tot 6 februari 2026, in het kader van het inkoopprogramma aangekondigd op 10 december 2025. InkoopdatumAantal verworven aandelenGemiddelde prijs (€)Laagste prijs (€)Hoogste prijs (€)Aankoop bedrag (€)2/2/2026-----2/2/2026-----2/2/2026-----2/2/20265.00053,8052,2056,55268.9952/2/20265.00053,1352,5053,45265.662TOTAAL10.00053,4752,2056,55534.657 Onde...
Melexis enters 2026 with a message that is far from triumphant: the recovery is happening, but it remains “an uneven recovery”. 4Q25 delivered growth, yes—but only just—and once again China dictated the rhythm with swings that overshadow structural progress. We updated our model taking into account management insists that FY26 will mark the start of margin improvement, and while the yield normalization story is credible, it does little to offset the uncomfortable reality of flat sales in 1Q an...
After today's changes (ASMi out, UCB in), we maintain a balanced approach in our Dynamic Top Pick List, with a particular emphasis on value stocks that have been overlooked. Our defensive holdings are overweight, including real estate, which stands to benefit from lower interest rates. We remove ASMi from our Dynamic Top Pick List as the recent share price performance has driven the valuation meaningfully ahead of fundamentals. Since early December, FY27 diluted EPS expectations have risen by a...
Melexis saw in 4Q25 still a challenging and unstable environment as the automotive industry demand continues to be cautious and choppy between quarters. They indicated they remain in an uneven recovery. Melexis highlighted that -looking at FY26- 1Q is traditionally impacted by annual customer pricing agreements and seasonal factors such as Chinese New Year and sales patterns outside of automotive. In addition, this year demand is affected by recent changes in EV automotive regulations and purcha...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.